Robuta

Sponsored by eBay https://www.oncodistinct.net/ Oncodistinct | network aiming to accelerate oncology drug development May 6, 2026 - Oncodistinct network is a non-profit research network aiming to accelerate oncology drug development and innovative strategies in clinical trials. to accelerateoncology drugnetworkaimingdevelopment https://www.post-gazette.com/business/healthcare-business/2023/07/22/predictive-oncology-ai-artificial-intelligence-tech-cmu-pitt-machine-learning/stories/202307200137 'Innovation and technology': Oncology drug development company using AI relocates to Pittsburgh |... innovation and technologydrug development company https://algokbio.com/ Oncology Drug Development | Algok Bio Mar 26, 2026 - We leverage our team's years of drug development experience to in-license promising leads and de-risk asset acquisition with our lead identification program. oncology drugdevelopmentbio https://www.london.edu/think/why-should-collaboration-enhance-oncology-drug-innovation Why should collaboration enhance oncology drug innovation | London Business School Sukhun Kang discusses the importance of collaborating between private and public businesses to increase oncology development oncology druglondon businesscollaborationenhanceinnovation https://odano.ca/ ODANO – Oncology Drug Navigators of Ontario oncology drugnavigatorsontario https://www.globenewswire.com/news-release/2024/06/20/2901371/0/en/Basilea-partners-oncology-drug-candidate-lisavanbulin-with-Glioblastoma-Foundation.html Basilea partners oncology drug candidate lisavanbulin with Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting... oncology drugbasileapartnerscandidate https://pmc.ncbi.nlm.nih.gov/articles/PMC12536354/ FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages... The maximum tolerated dose has historically been the recommended phase two dose, and this dosage has typically been evaluated in registrational clinical trials... oncology drugfdaaacrstrategiesoptimizing https://ailseoncology.com/ Experts in Oncology Drug Development Consulting experts inoncology drugdevelopmentconsulting https://www.stjude.org/education-training/advanced-training/seminars-symposia/science-of-childhood-cancer-series/science-of-childhood-cancer-blackman.html Opportunities and challenges in pediatric oncology drug development: Lessons learned from the... pediatric oncology https://pmc.ncbi.nlm.nih.gov/articles/PMC6376915/ Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology... Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints... https://marketrealist.com/2016/05/medivation-sees-growth-xtandi-major-oncology-drug/ Medivation Sees Growth in Xtandi: A Major Oncology Drug May 10, 2016 - Medivation (MDVN) is an oncology-focused biopharmaceutical company, and Xtandi as its only approved drug. a majormedivationseesgrowthxtandi https://www.biospace.com/massive-bio-announces-plans-to-expand-ai-use-in-oncology-from-clinical-trial-matching-to-drug-matching-and-beyond Massive Bio Announces Plans to Expand AI Use in Oncology, from Clinical Trial Matching to Drug... Jan 4, 2023 - Massive Bio , a leader in AI-powered cancer treatment, today announced plans to launch a new AI-powered drug matching product in 2023 that will enable... https://www.nyp.org/professionals/2019-innovations-reports-for-oncology/genitourinary-oncology/expanding-the-boundaries-of-drug-development Expanding the Boundaries of Drug Development - Genitourinary Oncology - 2019 Innovations Reports... Cora N. Sternberg, MD, a leading international researcher and expert in the field of medical oncology, genitourinary cancers, and drug development, serves as... drug developmentgenitourinary oncologyexpandingboundaries https://www.financialcontent.com/article/gnwcq-2026-2-19-drug-delivery-breakthroughs-cross-indication-research-accelerate-new-momentum-in-cns-and-oncology-development Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology... https://www.wolterskluwer.com/en/solutions/ovid/herbdrug-interactions-in-oncology-8126 Ovid - Herb-Drug Interactions in Oncology | Wolters Kluwer The book provides science-based information for the medical community about herbal remedies, other dietary supplements, and non-mainstream products promoted as... herb drug interactionsovidoncologywolterskluwer https://www.fda.gov/about-fda/oncology-center-excellence/about-oncology-prescription-drug-labeling About Oncology Prescription Drug Labeling | FDA About Oncology Prescription Drug Labeling prescription drugoncologylabelingfda https://pmc.ncbi.nlm.nih.gov/articles/PMC7014347/ The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology - PMC As many novel cancer therapies continue to emerge, the field of Cardio-Oncology (or onco-cardiology) has become crucial to prevent, monitor and treat cancer... the role ofdrug metabolismcardio oncologycyp450 https://www.news-medical.net/news/20251114/DeepTarget-A-new-tool-for-drug-repurposing-in-oncology.aspx DeepTarget: A new tool for drug repurposing in oncology Nov 15, 2025 - One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published... a newdrug repurposingtooloncology https://pmc.ncbi.nlm.nih.gov/articles/PMC9271471/ Duration of treatment in oncology clinical trials: does the duration change when the same drug... When a new drug comes to the market, the incentive for the sponsoring company is to maximize the treatment duration in order for the patient to reap the full... oncology clinical trials https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/ Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current... Anticancer treatment efficacy is limited by the development of refractory tumor cells characterized by increased expression and activity of mechanisms... https://www.biospace.com/shorla-oncology-announces-us-acquisition-of-jylamvo-an-oncology-and-autoimmune-drug-from-therakind Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind... Nov 1, 2023 - Shorla Oncology and Therakind Ltd, a UK-based specialty pharmaceutical company have entered into an agreement under which Shorla has agreed to acquire Jylamvo,... https://www.growkudos.com/publications/10.1101%25252F240846/reader The conduct of most first-in-human oncology drug trials is conceptually incoherent, and unethical.... When a new cancer drug is tried for the first time in cancer patients, we lack answers even to very basic questions about the drug: What range of doses can... https://informaconnect.com/immunooncology-race-to-find-magic-combination-drugs-to-kill-cancer/ Immuno-oncology: Race to find the magic drug combination to kill cancer find the magicimmuno oncologydrug combinationrace https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1121878/full Frontiers | Insights into immuno-oncology drug development landscape with focus on bone metastasis Bone is among the major sites of metastasis in breast, prostate and other major cancers. Bone metastases remain incurable causing high mortality, severe skel...